2 results
Approved WMORecruiting
Primary: To assess the proportion of patients with intervention failure at 12 months after dose reduction, defined as patients who have restarted their initial dose due to (expected) loss of major molecular response.
Approved WMORecruiting
Primary:Phase I: • To characterize the safety and tolerability and to identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and regimen for future studies of DYP688 as a single agent.Phase Il:• To evaluate the anti-tumor activity of…